In the 2014 (25) issue of Turkish Journal of Gastroenterology, Yıldız et al. (1) reported that the increase in troponin levels during ERCP may show cardiac damage. Patients undergoing ERCP, who were diagnosed in advance of having ischemic cardiac problems (n=48) and without cardiac problems (n=76), were recruited in this study. Before and after ERCP, ECG, blood pressure, heart rate, oxygen saturation levels, MPO, CPK, CK-MB, and cTnI levels were evaluated in both groups. The effectiveness of these parameters in demonstrating myocardial ischemia during ERCP was investigated. While there were no ECG changes in patients without coronary history, 11 patients (22.9%) had ECG changes that may indicate myocardial ischemia in the ischemic group during ERCP. This is a well designed and an observational study. There are contradictory results in silent myocardial ischemia during ERCP. While some publications indicate that cardiac damage is rare during ERCP (2%) (2,3), some studies indicate otherwise (10%-18%) (4,5).
This is a well designed and an observational study. There are contradictory results in silent myocardial ischemia during ERCP. While some publications indicate that cardiac damage is rare during ERCP (2%) (2, 3) , some studies indicate otherwise (10%-18%) (4, 5) .
In ERCP patients who were diagnosed in advance of having ischemic cardiac problems, post-ERCP ECG findings have been mentioned, but the pre-existing or newly emerged ECG findings were not specified in this study. In addition, how long the ST changes continued was not specified. Therefore, the recorded ECG changes are not clear, depending on the post-ERCP cardiac injury.
Johnston et al. (4) reported that in 9 patients (n: 41) who had ECG changes during ERCP, significant ECG changes were observed in 4 patients. However, there were significant ECG changes in only 1 of 9 patients who had cardiac history. In 3 patients, despite the absence of cardiac history, significant ECG changes were observed (4) . In another study involving 71 patients, Lee et al. reported that 9 patients (5.2%) without cardiac history developed ischemic ECG changes (5). In this study, in patients without cardiac history, lack of ECG changes is inconsistent with the literature cited above.
These criticisms in the last two paragraphs could be prevented in the following way, like Lee et al. did (4): 30 minutes before ERCP and post-ERCP for 24 hours, Holter ECG application could be made.
In a study, along 8 hours after ischemia, followed by measurements at least 3 times with 3-hour intervals, cTnI was seen as a highly effective test (6). Cullen et al. reported that highly sensitive cTnI measurements were found to be effective in 2 hours after ischemia (7). Another point is that the Siemens cTnI kit used in this study, in cardiac injury except for MI, does not rise significantly (8). Finally, if we will detect the presence of cardiac damage that occurred during the ERCP, cTnI changes that occurred pre-and post-ERCP must be demonstrated. According to the literature, cTnI is anticipated to increase 30-42% in cardiac injury (9,10). However, the authors measured cTnI levels only once and with standard methodology.
In summary, if we evaluate cardiac damage during ERCP, we need more detailed cardiological data. 
